CECLOR
LOE ApproachingNDAORALCAPSULE
Approved
Apr 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CECLOR is an oral cephalosporin antibiotic approved in 1979 by Eli Lilly for bacterial infections. The drug is a small-molecule beta-lactam antibiotic indicated for respiratory, urinary, and skin infections. It represents a mature, well-established antibiotic class with decades of clinical use.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), indicating a contracting team focused on managed decline and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CECLOR offers limited career growth potential given its LOE Approaching status and zero linked job openings. Career opportunities are primarily in defensive commercial roles focused on managed decline, generic transition, and market retention rather than expansion or innovation.
Brand ManagerField Sales Representative
Worked on CECLOR at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.